ATE255908T1 - Immunotoxinmischungen zur behandlung von immunkrankheiten. - Google Patents
Immunotoxinmischungen zur behandlung von immunkrankheiten.Info
- Publication number
- ATE255908T1 ATE255908T1 AT99910879T AT99910879T ATE255908T1 AT E255908 T1 ATE255908 T1 AT E255908T1 AT 99910879 T AT99910879 T AT 99910879T AT 99910879 T AT99910879 T AT 99910879T AT E255908 T1 ATE255908 T1 AT E255908T1
- Authority
- AT
- Austria
- Prior art keywords
- immunotoxin
- mixtures
- treatment
- immune diseases
- provides
- Prior art date
Links
- 230000002637 immunotoxin Effects 0.000 title abstract 2
- 231100000608 immunotoxin Toxicity 0.000 title abstract 2
- 208000026278 immune system disease Diseases 0.000 title 1
- 229940051026 immunotoxin Drugs 0.000 title 1
- 239000002596 immunotoxin Substances 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 238000000034 method Methods 0.000 abstract 1
- 238000007086 side reaction Methods 0.000 abstract 1
- 231100000167 toxic agent Toxicity 0.000 abstract 1
- 239000003440 toxic substance Substances 0.000 abstract 1
- 238000002054 transplantation Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6817—Toxins
- A61K47/6819—Plant toxins
- A61K47/6825—Ribosomal inhibitory proteins, i.e. RIP-I or RIP-II, e.g. Pap, gelonin or dianthin
- A61K47/6827—Ricin A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Toxicology (AREA)
- Cell Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Botany (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US7908698P | 1998-03-23 | 1998-03-23 | |
| EP98200917A EP0945139A1 (de) | 1998-03-23 | 1998-03-23 | Verfahren un Mitteln zur Herstellung von Immunkrankheiten wie Graft-Versus-Host-Krankheit |
| PCT/NL1999/000156 WO1999048534A1 (en) | 1998-03-23 | 1999-03-19 | Methods and means for the treatment of immune related diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE255908T1 true ATE255908T1 (de) | 2003-12-15 |
Family
ID=8233504
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT99910879T ATE255908T1 (de) | 1998-03-23 | 1999-03-19 | Immunotoxinmischungen zur behandlung von immunkrankheiten. |
Country Status (8)
| Country | Link |
|---|---|
| EP (2) | EP0945139A1 (de) |
| AT (1) | ATE255908T1 (de) |
| AU (1) | AU2964099A (de) |
| CA (1) | CA2325439A1 (de) |
| DE (1) | DE69913508T2 (de) |
| ES (1) | ES2213355T3 (de) |
| NZ (1) | NZ507171A (de) |
| WO (1) | WO1999048534A1 (de) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7601691B2 (en) | 1999-05-17 | 2009-10-13 | Conjuchem Biotechnologies Inc. | Anti-obesity agents |
| GB201717966D0 (en) | 2017-10-31 | 2017-12-13 | Xenikos Bv | Immunotoxins, formulations thereof and their use in medicine |
| AU2024282452A1 (en) | 2023-05-30 | 2025-11-27 | Philikos B.V. | Methods and means for the treatment of chronic inflammatory and autoimmune disease |
| WO2025202213A1 (en) | 2024-03-26 | 2025-10-02 | Institut National de la Santé et de la Recherche Médicale | Lipid nanoparticle loaded with antitumoral agent and functionnalized to target immosuppressive cells |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1989006967A1 (en) * | 1988-02-03 | 1989-08-10 | Xoma Corporation | Immunosupression with anti-pan t-cell immunotoxin compositions |
| FI105320B (fi) * | 1988-04-04 | 2000-07-31 | Oncogen | Menetelmä vasta-aineheterokonjugaattien valmistamiseksi, joita käytetään imusoluaktiivisuuden säätelyssä ja diagnoosissa |
| US5045451A (en) * | 1988-10-26 | 1991-09-03 | Board Of Regents | Methods for screening antibodies for use as immunotoxins |
-
1998
- 1998-03-23 EP EP98200917A patent/EP0945139A1/de not_active Withdrawn
-
1999
- 1999-03-19 DE DE69913508T patent/DE69913508T2/de not_active Expired - Lifetime
- 1999-03-19 WO PCT/NL1999/000156 patent/WO1999048534A1/en not_active Ceased
- 1999-03-19 AU AU29640/99A patent/AU2964099A/en not_active Abandoned
- 1999-03-19 ES ES99910879T patent/ES2213355T3/es not_active Expired - Lifetime
- 1999-03-19 AT AT99910879T patent/ATE255908T1/de not_active IP Right Cessation
- 1999-03-19 EP EP99910879A patent/EP1066058B1/de not_active Expired - Lifetime
- 1999-03-19 CA CA002325439A patent/CA2325439A1/en not_active Abandoned
- 1999-03-19 NZ NZ507171A patent/NZ507171A/en not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| ES2213355T3 (es) | 2004-08-16 |
| WO1999048534A1 (en) | 1999-09-30 |
| AU2964099A (en) | 1999-10-18 |
| EP0945139A1 (de) | 1999-09-29 |
| DE69913508D1 (de) | 2004-01-22 |
| EP1066058A1 (de) | 2001-01-10 |
| NZ507171A (en) | 2002-06-28 |
| DE69913508T2 (de) | 2004-09-23 |
| EP1066058B1 (de) | 2003-12-10 |
| CA2325439A1 (en) | 1999-09-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20026264D0 (no) | Fremgangsmåter for behandling av reumatoid artritt ved anvendelse av opplöselig mutant CTLA4 molekyl | |
| EP0528931A4 (en) | Humanized chimeric anti-icam-1 antibodies, methods of preparation and use | |
| DK1212422T3 (da) | Humane CTLA-4-antistoffer og anvendelserne deraf | |
| DE60139689D1 (de) | Kombination von CpG und Antikörpern gegen CD19,CD20,CD22 oder CD40 zur Prävention oder Behandlung von Krebs. | |
| ATE60697T1 (de) | Verfahren zur bekaempfung von pilzen. | |
| ATE483733T1 (de) | Hochaffine humane antikörper gegen tumorantigene | |
| DK1157042T3 (da) | Fremstilling af tetravalente antistoffer | |
| ATE191513T1 (de) | Verfahren zur amplifikation von nukleinsäuren | |
| MA27139A1 (fr) | Anticorps au cd40. | |
| DE69526684D1 (de) | Begasungsrührwerk zur Behandlung von Metallschmelzen | |
| DE69939058D1 (de) | Vorrichtung zur behandlung von peripheren gefässerkrankungen | |
| DE59915227D1 (de) | Verfahren zur Behandlung von biologischen Abfällen | |
| DE69027535D1 (de) | Modifiziertes biologisches material | |
| ATE228765T1 (de) | Zusammensetzung und verfahren zur behandlung von pflanzen mit exogenen chemikalien | |
| DE69613458D1 (de) | Anlage zur biologischen behandlung von wasser, um es trinkbar zu machen | |
| ATE495751T1 (de) | Behandlung von bauchspeicheldrüsenkrebs mit einem monoklonalen antikörper | |
| NO178186C (no) | Forbindelser som kan koble metallioner til biologisk nyttige molekyler | |
| DE69913508D1 (de) | Immunotoxinmischungen zur behandlung von immunkrankheiten. | |
| ATE257708T1 (de) | Kombinationen enthaltend vx478, zidovudin und 3tc zur behandlung von hiv | |
| DE59510667D1 (de) | Pyridylthioverbindungen zur bekämpfung von helicobacter-bakterien | |
| ATE495193T1 (de) | Bag3-antikörper zur nutzung in forschung, diagnose und der behandlung von krankheiten, an denen zelltod beteiligt ist | |
| DE3581703D1 (de) | Verfahren und vorrichtung zur biologischen behandlung von wasser, insbesondere zur denitrifikation von rohwasser zur trinkwasseraufbereitung. | |
| DE59109225D1 (de) | Verwendung von pyridylmethylsulfinyl-1h-benzimidazol derivaten zur behandlung durch helicobacter verursachter erkrankungen | |
| PT1112231E (pt) | Processo e instalacoes de tratamento de efluentes para pequenos povoados | |
| ATE288498T1 (de) | Methoden zur inhibierung von helicobacter pylori |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |